Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects

References

• Arnold TM, Forrest GN, Messmer KJ. Polymyxin antibiotics for gram-negative infections. Am J Health Syst Pharm 2007;64:819-26
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006;4:138-46
   PubMedGoogle Scholar
• Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601
   PubMed Web of Science ®Google Scholar
• Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009;22:535-43
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005a;40:1333-41
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-8
   PubMed Web of Science ®Google Scholar
• Brown JM, Dorman DC, Roy LP. Acute renal failure due to overdosage of colistin. Med J Aust 1970;2:923-4
   PubMed Web of Science ®Google Scholar
• Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-68
   PubMedGoogle Scholar
• Ryan KJ, Schainuck LI, Hickman RO, et al. Colistimethate toxicity. Report of a fatal case in a previously healthy child. JAMA 1969;207:2099-101
   Google Scholar
• Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005b;5:1
   PubMed Web of Science ®Google Scholar
• Couet W, Grégoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 2011;89:875-9
   PubMed Web of Science ®Google Scholar
• Gobin P, Lemaître F, Marchand S, et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 2010;54:1941-8
   PubMed Web of Science ®Google Scholar
• World Medical Association. Declaration of Helsinki – ethical principles for medical research involving human subjects. 2008
   Google Scholar
• Coly-Mycin M Parenteral Package Insert, 2007
   Google Scholar
• Li J, Milne RW, Nation RL, et al. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003a;47:1364-70
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6
   PubMed Web of Science ®Google Scholar
• Jansson B, Karvanen M, Cars O, et al. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal 2009;49:760-7
   PubMed Web of Science ®Google Scholar
• Galani I, Kontopidou F, Souli M, et al. Colistin susceptibility testing by Etest and disk diffusion methods. Int J Antimicrob Agents 2008;31:434-9
   PubMed Web of Science ®Google Scholar
• Dudhani RV, Li J, Nation RL. Plasma binding (PB) of colistin involves multiple proteins and is concentration dependent: potential clinical implications. 2009, 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, USA
   Google Scholar
• Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54:1117-24
   PubMed Web of Science ®Google Scholar
• Etherington C, Bosomworth M, Clifton I, et al. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros 2007;6:67-73
   PubMed Web of Science ®Google Scholar
• Price RG. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992;38:S14-19
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94
   PubMed Web of Science ®Google Scholar